EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical

Ablynx establishes subsidiary in the USA and appoints a general manager

Ablynx has announced the establishment of Ablynx, Inc., its subsidiary in the USA, and the appointment of Mr Daniel Schneider as the General Manager to lead the commercialisation of caplacizumab in North America. Mr Daniel (Dan) Schneider will be based in a US office, to be located on the East Coast. Caplacizumab is the Company’s wholly-owned anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).

 
Dan Schneider has 25 years of experience in establishing and leading the commercial operations for a number of companies in the life sciences industry and has been deeply involved in the successful launch of many pharmaceutical products, including those for orphan indications. Until recently, Dan was the General Manager of the Specialty Pharmaceuticals Business Unit at BTG International Inc. Previously, he held senior commercial roles at a number of life science companies where he developed the commercial strategy and led the sales efforts across all sectors of the business. Dan holds a BSBA from Saint Louis University and an MBA from Washington University in St. Louis.
 
Dr Edwin Moses, CEO of Ablynx, commented: “The establishment of Ablynx, Inc. is an important milestone for the Company and confirms our commitment to becoming a fully integrated international biopharmaceutical company. We are very pleased that Dan is joining us. He brings many years of experience in setting up commercial organisations and leading multiple successful product launches in the USA. We look forward to joining forces to further develop our commercial infrastructure in preparation of the potential launch of caplacizumab.”
 
Commenting on his appointment, Mr Schneider added: I am delighted to join Ablynx at this very important moment as the Company prepares for the potential launch of its first product. I look forward to building and leading the commercial activities in North America and contributing to the growth of the Company.”
 
 
 
 
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18